title: Tryptase as an inflammatory marker in allergic disease and asthma.
abstract: Asthma is a chronic inflammatory disease of the airways, varying from occasional episodes of wheezing and shortness of breath, to an irreversible, life-threatening obstructive disease. While many cases are managed with relative ease, others do not respond to the traditional inhaled therapy or even to oral glucocorticosteroids. Although it cannot be cured as yet, asthma can be controlled if properly diagnosed. Usually, functional clinical parameters form the basis for estimation of the disease severity. In addition, the growing database of cytokine and mediator profiles have allowed their exploitation as molecular markers for processes underlying airway inflammation in asthma. Tryptase is a potent and versatile mediator in allergic inflammation, orchestrating both acute and chronic events by acting on a vast array of cells and tissue components. For more than a decade, tryptase has been used as a marker for allergic inflammation in asthma as well as in a variety of other airway diseases. In this review, the current advantages and disadvantages of the use of tryptase as an inflammatory marker in asthma will be discussed.
authors.affiliation: The Hebrew University of Jerusalem, Department of Pharmacology, Jerusalem 91120, Israel. idobach@md.huji.ac.il
authors.forename: Ido
authors.initials: I
authors.lastname: Bachelet
authors.forename: Ariel
authors.initials: A
authors.lastname: Munitz
authors.forename: Francesca
authors.initials: F
authors.lastname: Levi-Schaffer